API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. LSE /
  3. 0RV2.LSE

BioArctic AB Series B (0RV2 LSE) stock market data APIs

kr182.4 0(0%) as of September 6, 2024
Price chart is built with Anychart

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

BioArctic AB Series B Financial Data Overview

182.4
182.4
-
225.5625
182.4
143.3-315.6
8 235 M
0
299 M
-0.7746
-0.191
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '0RV2',
Type: 'Common Stock',
Name: 'BioArctic AB Series B',
Exchange: 'LSE',
CurrencyCode: 'SEK',
CurrencyName: 'Swedish krone',
CurrencySymbol: 'kr',
CountryName: 'UK',
CountryISO: 'GB',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: '',
Industry: '',
}

BioArctic AB Series B Fundamental Data is available in our Financial Data APIs

  • Net Revenue 299 M
  • EBITDA -74 368 000
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get BioArctic AB Series B Earnings via APIs

  • Latest Release 2024-08-29
  • EPS/Forecast NaN

Get BioArctic AB Series B End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get BioArctic AB Series B latest news via APIs

Eisai increases the number of participants in Clarity AD study

STOCKHOLM, Feb. 3, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in th...
  • AD
  • ALZHEIMER'S DISEASE
  • BIOARCTIC AB
  • CLARITY
  • CLARITY AD
  • EISAI
  • FDA

Eisai increases the number of participants in Clarity AD study

STOCKHOLM, Feb. 3, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in th...
  • AD
  • ALZHEIMER'S DISEASE
  • BIOARCTIC AB
  • CLARITY
  • CLARITY AD
  • EISAI
  • FDA
Do you have any questions?
support@eodhistoricaldata.com